FBXL20 acts as an invasion inducer and mediates E-cadherin in colorectal adenocarcinoma

Oncology Letters

Volumn 7, Issue 6, 2014, Pages 2185-2191

  Zhu, Jianjun ^a   Deng, Shishan ^a   Duan, Jie ^a   Xie, Xingguo ^a   Xu, Shiquan ^a   Ran, Maocheng ^a   Dai, Xiaosi ^a   Pu, Yu ^a   Zhang, Xiaoming ^a  

^a AFFILIATED HOSPITAL OF NORTH SICHUAN MEDICAL COLLEGE   (China)

Author keywords

Colorectal adenocarcinoma; E cadherin; FBXL20; Invasion

Indexed keywords

AXIN; BETA CATENIN; CASPASE 3; MYC PROTEIN; PHOSPHOPROTEIN PHOSPHATASE 2A; PROTEIN P53; UVOMORULIN;

ARTICLE; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; COLORECTAL CARCINOMA; CONTROLLED STUDY; DOWN REGULATION; FBXL20 GENE; GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; ONCOGENE; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; SET NUCLEAR ONCOGENE; UPREGULATION; WESTERN BLOTTING; WOUND HEALING;

EID: 84898848726     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2014.2031     Document Type: Article

References (27)

1. Vonlaufen A, Troillet FX and Armenian B: Screening for colorectal cancer: recommendations. Rev Med Suisse 9: 754-757, 2013 (In French).
2. Du XL, Cai Y and Symanski E: Association between chemotherapy and cognitive impairments in a large cohort of patients with colorectal cancer. Int J Oncol 42: 2123-2133, 2013.
3. George B and Kopetz S: Predictive and prognostic markers in colorectal cancer. Curr Oncol Rep 13: 206-215, 2011.
4. Ren F, Sheng WQ and Du X: CD33: a cancer stem cells marker, is used in colorectal cancers. World J Gastroentrol 19: 2603-2611, 2013.
5. Smith JC, Brooks L, Hoff PM, et al: KRAS mutations are associated with inferior clinical outcome in patients with metastatic colorectal cancer, but are not predictive for benefit with cediranib. Eur J Cancer 49: 2424-2432, 2013.
6. Haugen MH, Johansen HT, Pettersen SJ, et al: Nuclear legumain activity in colorectal cancer. PLoS One 8: e52980, 2013.
7. Welcker M, Larimore EA, Frappier L and Clurman BE: Nucleolar targeting of the fbw7 ubiquitin ligase by a pseudosubstrate and glycogen synthase kinase 3. Mol Cell Biol 31: 1214-1224, 2011.
8. Miranda-Carboni GA, Krum SA, Yee K, et al: A functional link between Wnt signaling and SKP2-independent p27 turnover in mammary tumors. Genes Dev 22: 3121-3134, 2008.
9. Zhu JJ, Li K, Dong L and Chen Y: Role of FBXL20 in human colorectal adenocarcinoma. Oncol Rep 28: 2290-2298, 2012.
10. Amold HK, Zhang X, Daniel CJ, et al: The Axin1 scaffold protein formation of a degradation complex for c-Myc. EMBO J 28: 500-512, 2009.
11. Grim JE, Knoblaugh SE, Guthrie KA, et al: Fbw7 and p53 cooperatively suppress advanced and chromosomally unstable intestinal cancer. Mol Cell Biol 32: 2160-2167, 2012.
12. Kiatagawa M, Hatakeyama A, Shirane M, et al: An F-box protein, FWD1, mediates ubiquitin-dependent proteolysis of beta-catenin. EMBO J 18: 2401-2410, 1999.
13. Micel LN, Tentler JJ, Smith PG and Eckhardt GS: Role of ubiquitin ligases and the protesasome in oncogenesis: novel targets for anticancer therapies. J Clin Oncol 31: 1231-1238, 2013.
14. Bromberg KD, Kluger HM, Delaunay A, et al: Increased expression of the E3 ubiquitin ligase RNF5 is associated with decreased survival in breast cancer. Cancer Res 67: 8172-8179, 2007.
15. Tsai YC, Mendoza A, Mariano JM, et al: The ubiquitin ligase gp78 promotes sarcoma metastasis by targeting KAI1 for degradation. Nat Med 13: 1504-1509, 2007.
16. Kioras K, Konstantara A, Kotoula V, et al: The prognostic significance of WNT pathway in surgically-treated colorectal cancer: β-catenin expression predicts for disease-free survival. Anticancer Res 33: 4573-4584, 2013.
17. Freeman TJ, Smith JJ, Chen X, et al: Smad4-mediated signaling inhibits intestinal neoplasia by inhibiting expression of β-catenin. Gastroenterology 142: 562-571, 2012.
18. Kanwar SS, Yu Y, Nautiyal J, et al: The Wnt/beta-catenin pathway regulates growth and maintenance of colonospheres. Mol Cancer 9: 212, 2010.
19. Liu KH, Huynh N, Patel O, et al: P21-activated kinase 1 promotes colorectal cancer survival by up-regulation by hypoxia-inducible factor-1α. Cancer Lett 340: 22-29, 2013.
20. Wu J, Xie N, Xie K, Zeng J, et al: GPR48, a poor prognostic factor, promotes tumor metastatis and activates β-catenin/TCF signaling in colorectal cancer. Carcinogenesis 34: 2861-2869, 2013.
21. Guo S, Xu J, Xue R, et al: Overexpression of A1BI correlates inversely with E-cadherin expression in pancreatic adenocarcinoma and may promote lymph node metastasis. Int J Clin Oncol March 30, 2013 (Epub ahead of print).
22. Oikawa T, Nakamura A, Onishi N, et al: Acquired expression of NFATc1 downregulates E-cadherin and promotes cancer cell invasion. Cancer Res 73: 5100-5109, 2013.
23. Huang C: Roles of E3 ubiquitin ligases in cell adhesion and migration. Cell Adh Migr 4: 10-18, 2010.
24. Li Q, He Y, Wei L, et al: AXIN is an essential co-activator for the promyelocytic leukemia protein in p53 activation. Oncogene 30: 1194-1204, 2011.
25. Yang LH, Xu HT, Han Y, et al: Axin downregulates TCF-4 transcription via beta-catenin, but not p53, and inhibits the proliferation and invasion of lung cancer cells. Mol Cancer 9: 25, 2010.
26. Ikeda S, Kishida M, Matsuura Y, et al: GSK-3beta-dependent phosphorylation of adenomatous polyposis coli gene product can be modulated by beta-catenin and protein phosphatase 2A complexed with Axin. Oncogene 19: 537-545, 2000.
27. Irie A, Harada K, Araki N and Nishimura Y: Phosphorylation of SET protein at Ser171 by protein kinase D2 diminishes its inhibitory effect on protein phosphatase 2A. PloS One 7: e51242, 2012.